118O Definitive Results for NSCLC and Bladder Cancer Cohorts in the Phase IIa Trial of Visugromab (CTL-002) in Advanced/metastatic Anti-Pd/pd-l1 Relapsed/refractory Solid Tumors (Gdfather-Trial)
Immuno-Oncology and Technology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined